Our data suggest that AS-IV may ameliorate hyperglycemia and inhibit the NOD2-related NF-κB signaling, which crosstalks with the MAPK signaling, attenuating inflammation in DN rats. This evidence concerns the gene NFKB1 and liver dysplastic nodule.